Cutaneous Adverse Drug Reaction to Oral Acetazolamide and Skin Tests
M. Jachiet(Assistance Publique – Hôpitaux de Paris), A. Soria(Inserm), S. Oro(Hôpitaux Universitaires Henri-Mondor), E. Amsler(Sorbonne Université), C. Françès(Navarre Institute of Health Research), H. Gaouar(Sorbonne Université), J.‐L. Bourrain(Hôpital Saint Eloi), É. Bégon(Centre Hospitalier René-Dubos), O. Chosidow(Sorbonne Université), N. Bellon(Hôpitaux Universitaires Henri-Mondor), H. Assier(Centre Hospitalier Universitaire Henri-Mondor), C. Pecquet(Ludwig Cancer Research)
Cited by 17
Related Papers
European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes
|Journal of the European Academy of Dermatology and Venereology|2017|262
Skin Thickness Changes in Normal Aging Skin
|Gerontology|2009|258
Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response
|Science Translational Medicine|2013|246
Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients
|Annals of the Rheumatic Diseases|2007|235
Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France
|Journal of the American Academy of Dermatology|2020|189